ViroMed receives US FDA Approval of Phase II trial for VM202

ViroMed Co., a local pharmaceutical firm, announced on July 21 that VM202-PAD, the company’s proprietary DNA medicine for the treatment of peripheral artery disease (PAD), has received approval from the US Food and Drug Administration for a Phase II clinical trial.

The trial will be performed under the supervision of the Principal Investigator, Dr. Timothy Henry of Minneapolis Heart Institu...